Gilead Sciences, Inc. (GILD)
$
114.54
+1.30 (1.13%)
Key metrics
Financial statements
Free cash flow per share
7.9005
Market cap
142.5 Billion
Price to sales ratio
4.9586
Debt to equity
1.3022
Current ratio
1.3693
Income quality
1.7378
Average inventory
1.7 Billion
ROE
0.3171
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Gilead Sciences, Inc. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of medicines addressing unmet medical needs in the United States, Europe, and internationally. The company has achieved a significant net income of $480,000,000.00 showcasing its strong financial health. The diluted EPS is $0.38 accounting for potential share dilution, which is an important metric for investors. Furthermore, the net income ratio stands at 0.02 reflecting the company's profitability margin effectively. Gilead's EBITDA is $4,434,000,000.00 serving as a key indicator of its operational profitability. Additionally, the gross profit ratio of 0.78 reflects the efficiency of the company's production and sales operations. The product portfolio includes Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla for HIV/AIDS treatment, as well as Veklury for COVID-19. Gilead also offers therapies for liver diseases, hematology, oncology, and related cell therapies. The company's collaborations with notable partners such as Arcus Biosciences, Pionyr Immunotherapeutics, and Bristol-Myers Squibb exemplify its strategic approach to innovation. Incorporated in 1987, Gilead is headquartered in Foster City, California. The stock is reasonably priced at $114.54 appealing to a broad range of investors. With a large market capitalization of $142,479,742,200.00 the company is a dominant player in the biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth within its category. Moreover, the stock has a high average trading volume of 8,502,193.00 indicating strong liquidity, which is an essential factor for investors seeking reliable investments. By fulfilling unmet medical needs and maintaining strong financial metrics, Gilead Sciences continues to be a vital entity in its field, dedicated to providing effective solutions for serious health conditions while upholding a commitment to improvement and advancement in biopharmaceutical science.
Is {{companyName}} ({{ticker}}) a good investment?
Investing in {{companyName}} ({{ticker}}) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as {{analystRating}}, with a {{bullishOrBearishOutlook}} outlook. Always conduct your own research before investing.
What is {{companyName}} ({{ticker}})'s stock forecast?
Analysts predict {{companyName}} stock to fluctuate between ${{priceTargetLow}} (low) and ${{priceTargetHigh}} (high) in the next {{forecastPeriod}}, reflecting market expectations and potential volatility.
What is {{companyName}}'s market capitalization?
As of {{lastUpdatedTime}}, {{companyName}}'s market cap is ${{marketCap}}, based on {{outstandingShares}} outstanding shares.
How does {{companyName}} compare to competitors like {{competitorName}}?
Compared to {{competitorName}}, {{companyName}} has a {{higherOrLower}} {{comparisonMetric}}, indicating a difference in performance.
Does {{companyName}} pay dividends?
{{companyName}} pays dividends. The current dividend yield is {{dividendYield}}%, with a payout of ${{dividendPerShare}} per share.
How can I buy {{companyName}} ({{ticker}}) stock?
To buy {{companyName}} ({{ticker}}) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for {{ticker}}. Place an order (Market, Limit, etc.).
What is the best time to invest in {{companyName}}?
The best time to invest depends on market trends and technical indicators, which show a {{bullishOrBearishOutlook}} trend based on economic conditions and company performance.
Has {{companyName}} stock ever split?
{{companyName}}'s last stock split was {{splitRatio}} on {{splitDate}}.
What is {{companyName}}'s price target for this year?
Analyst price targets range from ${{priceTargetHigh}} to ${{priceTargetLow}}, with an average of ${{priceTargetAvg}}.
How did {{companyName}} perform in the last earnings report?
Revenue: ${{lastRevenue}} | EPS: ${{lastEPS}} | Growth: {{growthRate}}%.
Where can I find {{companyName}}'s investor relations reports?
Visit {{companyWebsite}}/investor-relations for detailed financial reports.
Where can I find historical stock prices for {{companyName}}?
You can explore historical data from here
What is the all-time high and low for {{companyName}} stock?
All-time high: ${{allTimeHigh}} ({{highDate}}) | All-time low: ${{allTimeLow}} ({{lowDate}}).
What are the key trends affecting {{companyName}} stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.
businesswire.com
MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir. Today's announcement of a pricing and procurement deal between Gilead and the Global Fund to Fight AIDS, Tuberculosis and Malaria leaves most countries in the region out, forcing them to negotiate individually and in secrecy. “Once again, Latin America and the Caribbean.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
zacks.com
Here is how Gilead Sciences (GILD) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
prnewswire.com
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
fool.com
Explore the exciting world of Gilead Sciences (GILD 0.79%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
globenewswire.com
NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
See all news
